Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORPHEUS LIVER umbrella study in advanced liver cancer
MOH_2020-08-13_009150Phase 2Recruiting
- Sponsor
- Roche
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, bevacizumab, HS-10516 and IO-108 in hepatocellular carcinoma (HCC) and liver cancer (5 arms), sponsored by Roche. Started Jul 2020; status: recruiting.
02
Drugs
atezolizumabbevacizumabHS-10516IO-108
03
Conditions
hepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on MOH_2020-08-13_009150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-08-13_009150.